Ascendiant Capital Starts Aastrom Biosciences (ASTM) at Strong Buy; Leading Pure Play in Regenerative Medicine
Tweet
Share
E-mailGet Alerts ASTM Hot Sheet
Price: $2.77 --0%
Rating Summary:
8 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 8 | New: 5
Rating Summary:
8 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 8 | New: 5
Join SI Premium – FREE
Ascendiant Capital initiates coverage on Aastrom Biosciences (NASDAQ: ASTM) with a Strong Buy. PT $4.25.
Analyst, Keay Nakae, said, "We believe that Aastrom is one of the best positioned, pure play regenerative medicine companies. The Company’s key product, ixmyelocel-T, is an autologous, bone marrow-derived cell therapy product being developed for the treatment of critical limb ischemia (CLI) and dilated cardiomyopathy (DCM). Aastrom has begun patient enrollment in a Phase 3 study for CLI, while DCM is in Phase 2."
For an analyst ratings summary and ratings history on Aastrom Biosciences click here. For more ratings news on Aastrom Biosciences click here.
Shares of Aastrom Biosciences closed at $2.32 yesterday.
Analyst, Keay Nakae, said, "We believe that Aastrom is one of the best positioned, pure play regenerative medicine companies. The Company’s key product, ixmyelocel-T, is an autologous, bone marrow-derived cell therapy product being developed for the treatment of critical limb ischemia (CLI) and dilated cardiomyopathy (DCM). Aastrom has begun patient enrollment in a Phase 3 study for CLI, while DCM is in Phase 2."
For an analyst ratings summary and ratings history on Aastrom Biosciences click here. For more ratings news on Aastrom Biosciences click here.
Shares of Aastrom Biosciences closed at $2.32 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Upgrades UDR, Inc. (UDR) to Buy
- Berenberg Starts Lloyds TSB Group (LYG) at Hold, 'shares are fairly valued'
- UBS Starts Mobimo Holding AG (MOBN:SW) at Neutral
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
